<DOC>
	<DOCNO>NCT01086800</DOCNO>
	<brief_summary>This study examine role sleep apnea treatment improve cardiovascular biomarkers .</brief_summary>
	<brief_title>Heart Biomarker Evaluation Apnea Treatment</brief_title>
	<detailed_description>This Phase II randomize control trial evaluate effect supplemental nocturnal oxygen Positive Airway Pressure ( PAP ) therapy , compare optimal medical preventive therapy Cardiovascular Disease ( CVD ) risk , biomarkers CVD risk Obstructive Sleep Apnea ( OSA ) patient high risk CVD event . The study focus patient moderate severe OSA mild OSA symptom . Eligible participant history symptom heart disease AND symptoms sleep apnea snore . Participants contribute medical knowledge different option use improve heart disease people sleep apnea .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>establish Coronary Artery Disease establish cardiovascular disease risk factor home sleep test show moderately severe sleep apnea poorly control health currently use supplemental oxygen PAP OSA</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>